share_log

S-1: General form for registration of securities under the Securities Act of 1933

S-1: General form for registration of securities under the Securities Act of 1933

S-1：证券上市注册声明
美股SEC公告 ·  08/19 06:43

Moomoo AI 已提取核心信息

Cingulate Inc., a biopharmaceutical company, has filed a Form S-1 with the Securities and Exchange Commission (SEC) on August 19, 2024, for a registration statement under the Securities Act of 1933. This filing pertains to the potential sale of up to 1,000,000 shares of common stock by Lincoln Park Capital Fund, LLC (Lincoln Park), a selling stockholder. The shares may be sold from time to time in various types of transactions, including ordinary broker transactions and direct sales. The registration allows for the sale of these shares by Lincoln Park at market prices or at negotiated prices. Cingulate Inc. will not receive any proceeds from the sale of shares by Lincoln Park. The company has previously entered into a Purchase Agreement with Lincoln Park, which allows Cingulate to direct Lincoln Park to purchase up to $12 million of its common stock, subject to certain conditions and limitations. As of the filing date, Cingulate's common stock and warrants are listed on the Nasdaq under the symbols 'CING' and 'CINGW' respectively.
Cingulate Inc., a biopharmaceutical company, has filed a Form S-1 with the Securities and Exchange Commission (SEC) on August 19, 2024, for a registration statement under the Securities Act of 1933. This filing pertains to the potential sale of up to 1,000,000 shares of common stock by Lincoln Park Capital Fund, LLC (Lincoln Park), a selling stockholder. The shares may be sold from time to time in various types of transactions, including ordinary broker transactions and direct sales. The registration allows for the sale of these shares by Lincoln Park at market prices or at negotiated prices. Cingulate Inc. will not receive any proceeds from the sale of shares by Lincoln Park. The company has previously entered into a Purchase Agreement with Lincoln Park, which allows Cingulate to direct Lincoln Park to purchase up to $12 million of its common stock, subject to certain conditions and limitations. As of the filing date, Cingulate's common stock and warrants are listed on the Nasdaq under the symbols 'CING' and 'CINGW' respectively.
生物医药公司Cingulate Inc.于2024年8月19日向美国证券交易委员会（SEC）提交了S-1表格，申请根据1933年证券法的注册声明。此次申报涉及由售出股权方Lincoln Park Capital Fund，LLC（Lincoln Park）出售多达100万股普通股。这些股份可以在各种交易中出售，包括普通经纪人交易和直销交易。注册声明允许Lincoln Park以市场价格或协商价格出售这些股票。Cingulate Inc.将不会从Lincoln Park售出的股份中获得任何收益。该公司此前已经与Lincoln Park签订了购买协议，允许Cingulate指示Lincoln Park购买其多达1200万美元的普通股，但受到某些条件和限制的限制。截至申报日，Cingulate的普通股和认股权证分别在纳斯达克上市，代码为“CING”和“CINGW”。
生物医药公司Cingulate Inc.于2024年8月19日向美国证券交易委员会（SEC）提交了S-1表格，申请根据1933年证券法的注册声明。此次申报涉及由售出股权方Lincoln Park Capital Fund，LLC（Lincoln Park）出售多达100万股普通股。这些股份可以在各种交易中出售，包括普通经纪人交易和直销交易。注册声明允许Lincoln Park以市场价格或协商价格出售这些股票。Cingulate Inc.将不会从Lincoln Park售出的股份中获得任何收益。该公司此前已经与Lincoln Park签订了购买协议，允许Cingulate指示Lincoln Park购买其多达1200万美元的普通股，但受到某些条件和限制的限制。截至申报日，Cingulate的普通股和认股权证分别在纳斯达克上市，代码为“CING”和“CINGW”。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间